ReviewTrends in molecular medicine2011
Mixing the right hepatitis C inhibitor cocktail.
Review in Trends in molecular medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Structure-based discovery of dual pathway inhibitors for SARS-CoV-2 entry.Nature communications · 2023Article
- Personalized medicine in non-small cell lung cancer: a review from a pharmacogenomics perspective.Acta pharmaceutica Sinica. B · 2018Review
- Lobohedleolide suppresses hepatitis C virus replication via JNK/c-Jun-C/EBP-mediated down-regulation of cyclooxygenase-2 expression.Scientific reports · 2018Article
- IDX-184 is a superior HCV direct-acting antiviral drug: a QSAR study.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2016Article
- Human Transbodies to HCV NS3/4A Protease Inhibit Viral Replication and Restore Host Innate Immunity.Frontiers in immunology · 2016Article
- Rational Design and Adaptive Management of Combination Therapies for Hepatitis C Virus Infection.PLoS computational biology · 2015Article
- Article
- Hepatitis C virus attenuates mitochondrial lipid β-oxidation by downregulating mitochondrial trifunctional-protein expression.Journal of virology · 2015Article
- Article
- Human Ebola virus infection in West Africa: a review of available therapeutic agents that target different steps of the life cycle of Ebola virus.Infectious diseases of poverty · 2014Article
- Response of hepatitis C virus to long-term passage in the presence of alpha interferon: multiple mutations and a common phenotype.Journal of virology · 2013Article
- Hepatitis C virus resistance to new specifically-targeted antiviral therapy: A public health perspective.World journal of virology · 2013Review
- Molecular modeling comparison of the performance of NS5b polymerase inhibitor (PSI-7977) on prevalent HCV genotypes.The protein journal · 2013Article
- Extinction of hepatitis C virus by ribavirin in hepatoma cells involves lethal mutagenesis.PloS one · 2013Article
- Model membrane platforms for biomedicine: case study on antiviral drug development.Biointerphases · 2012Review
- Human subtilase SKI-1/S1P is a master regulator of the HCV Lifecycle and a potential host cell target for developing indirect-acting antiviral agents.PLoS pathogens · 2012Article
- New developments in the management of hepatitis C virus infection: focus on boceprevir.Biologics : targets & therapy · 2012Article
- Self-assembling peptide nanotubes with antiviral activity against hepatitis C virus.Chemistry & biology · 2011Article
- Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus.Nature biotechnology · 2011Article
- Knockdown of USP18 increases α 2a interferon signaling and induction of interferon-stimulating genes but does not increase antiviral activity in Huh7 cells.Antimicrobial agents and chemotherapy · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Therapy for hepatitis C virus (HCV) infection is on the cusp of a new era. Until now, standard-of-care therapy has involved interferon (IFN) and ribavirin. With the first successful Phase III trials of specific targeted antiviral therapy for HCV (STAT-C) compounds, as well as three trials in progress giving the first glimpse of IFN-free combinations of STAT-C agents, this review looks ahead to the new classes of anti-HCV agents currently in clinical development. Successful pharmacologic control of HIV and TB frames the discussion, as well as consideration of the mutation frequency of HCV replication. Maximizing synergy between agents and minimizing cumulative toxicity will be critical to the design of future IFN-free STAT-C regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.